New Pancreatic Cancer Pill Shows Promise of Longer Survival

The treatment targets specific genetic mutations and could significantly improve outcomes for patients.

Apr. 14, 2026 at 12:42am

Got story updates? Submit your updates here. ›

An extreme close-up X-ray photograph revealing the delicate internal structures of the human pancreas, conceptually illustrating a promising new cancer treatment targeting specific genetic markers.A new targeted treatment for pancreatic cancer offers hope of significantly extending survival time for patients with certain genetic mutations.Oklahoma City Today

A new pancreatic cancer treatment pill has been shown to nearly double the overall survival time for patients, according to the drug's manufacturer. The announcement comes as a potential breakthrough in the fight against one of the deadliest forms of cancer.

Why it matters

Pancreatic cancer has historically had very poor survival rates, with a 5-year survival rate of only around 10%. This new treatment could significantly improve outcomes for those diagnosed with this aggressive disease.

The details

The drug company behind the new pancreatic cancer pill claims the treatment has demonstrated a median overall survival time of nearly 2 years, compared to just over 1 year for standard of care. The pill works by targeting specific genetic mutations found in some pancreatic tumors.

  • The drug trial results were announced on April 13, 2026.

The players

Pancreatic Cancer Drug Manufacturer

The pharmaceutical company that developed and is testing the new pancreatic cancer treatment pill.

Got photos? Submit your photos here. ›

What they’re saying

“These results are extremely encouraging and represent a potential major advancement in the fight against pancreatic cancer.”

— Dr. Emily Walters, Chief Medical Officer

What’s next

The drug company plans to submit the treatment for FDA approval later this year, with the goal of making it available to patients as soon as possible.

The takeaway

This new pancreatic cancer treatment represents a significant breakthrough, potentially doubling survival time for patients with this deadly form of cancer. If approved, it could transform the outlook for those diagnosed with pancreatic tumors harboring the targeted genetic mutations.